Pegylated interferon-alpha plus ribavirin combination (PegIFN/RBV) therapy possesses positive effect in the secondary prevention of hepatocellular carcinoma (HCC) in chronic hepatitis C (CHC) patients. The current study aimed to assess its efficacy in the tertiary prevention and to validate the performance of the MHC class I polypeptide-related chain A (MICA) level in the prediction of hepatocellular carcinoma (HCC) recurrence.A multi-center study enrolling 105 consecutive HCC patients post curative therapies were prospectively recruited. The primary outcome measurement was recurrence of HCC.The mean observational period was 52.7 months (range = 3.9-121.5 months). Fifty-six (53.3

作者：Jee-Fu, Huang；Ming-Lun, Yeh；Ming-Lung, Yu；Chia-Yen, Dai；Chung-Feng, Huang；Ching-I, Huang；Pei-Chien, Tsai；Pei-Chen, Lin；Yao-Li, Chen；Wen-Tsan, Chang；Nai-Jen, Hou；Zu-Yau, Lin；Shinn-Cherng, Chen；Wan-Long, Chuang

来源：Journal of gastroenterology and hepatology 2015 年 30卷 12期